Electrocore LLC - Asset Resilience Ratio
Electrocore LLC (ECOR) has an Asset Resilience Ratio of 25.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Electrocore LLC's Asset Resilience Ratio has changed over time. Check how strategically is Electrocore LLC's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Electrocore LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Electrocore LLC market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.98 Million | 25.69% |
| Total Liquid Assets | $3.98 Million | 25.69% |
Asset Resilience Insights
- Very High Liquidity: Electrocore LLC maintains exceptional liquid asset reserves at 25.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Electrocore LLC Industry Peers by Asset Resilience Ratio
Compare Electrocore LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Electrocore LLC (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Electrocore LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.51% | $4.58 Million | $18.67 Million | -17.10pp |
| 2024-12-31 | 41.61% | $8.52 Million | $20.47 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $16.10 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $42.83 Million | -- |
| 2020-12-31 | 58.34% | $18.39 Million | $31.52 Million | +28.74pp |
| 2019-12-31 | 29.60% | $10.50 Million | $35.46 Million | -53.34pp |
| 2018-12-31 | 82.94% | $60.96 Million | $73.50 Million | +21.89pp |
| 2017-12-31 | 61.05% | $23.95 Million | $39.23 Million | -- |
About Electrocore LLC
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic… Read more